{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:01:49Z","timestamp":1789750909180,"version":"4.0.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jconrel.2026.115145","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T16:05:13Z","timestamp":1782749113000},"page":"115145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Integrating PD-L1-targeted radioligand with protein degradation for precision tumor theranostics"],"prefix":"10.1016","volume":"397","author":[{"given":"Qinglin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongqiang","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwei","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianzhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhide","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.115145_bb0005","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41570-025-00784-6","article-title":"Lessons learned in linking PROTACs from discovery to the clinic","volume":"10","author":"Pike","year":"2026","journal-title":"Nat. Rev. Chem."},{"key":"10.1016\/j.jconrel.2026.115145_bb0010","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/s41422-021-00533-6","article-title":"Merging PROTAC and molecular glue for degrading BTK and GSPT1 proteins concurrently","volume":"31","author":"Yang","year":"2021","journal-title":"Cell Res."},{"key":"10.1016\/j.jconrel.2026.115145_bb0015","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41392-025-02444-z","article-title":"In vivo self-assembled nano-PROTAC for the dual degradation of AR and HSP90 to overcome castration-resistant prostate cancer resistance","volume":"10","author":"Yang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.115145_bb0020","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115145_bb0025","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/d41573-021-00052-4","article-title":"Targeted protein degraders crowd into the clinic","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115145_bb0030","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.3390\/cells10092250","article-title":"Epitranscriptomic approach: to improve the efficacy of ICB therapy by co-targeting intracellular checkpoint CISH","volume":"10","author":"Kumar","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jconrel.2026.115145_bb0035","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2026.115145_bb0040","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12943-024-02059-y","article-title":"PD1\/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives","volume":"23","author":"Zhu","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2026.115145_bb0045","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.cell.2018.11.021","article-title":"Organoid modeling of the tumor immune microenvironment","volume":"175","author":"Neal","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115145_bb0050","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009710","article-title":"Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses","volume":"12","author":"Dong","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2026.115145_bb0055","article-title":"Targeted degradation of PD-L1 and activation of the STING pathway by carbon-dot-based PROTACs for Cancer immunotherapy","volume":"62","author":"Su","year":"2023","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.jconrel.2026.115145_bb0060","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1021\/jacs.0c10008","article-title":"Development of antibody-based PROTACs for the degradation of the cell-surface immune checkpoint protein PD-L1","volume":"143","author":"Cotton","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2026.115145_bb0065","article-title":"Self-assembled peptide-derived proteolysis-targeting chimera (PROTAC) nanoparticles for tumor-targeted and durable PD-L1 degradation in Cancer immunotherapy","volume":"64","author":"Moon","year":"2025","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.jconrel.2026.115145_bb0070","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13045-020-01027-5","article-title":"Regulation of PD-L1 expression in the tumor microenvironment","volume":"14","author":"Yi","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2026.115145_bb0075","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.115145_bb0080","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/nrclinonc.2017.88","article-title":"Monitoring immune checkpoint blockade: response evaluation and biomarker development","volume":"14","author":"Nishino","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.115145_bb0085","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s00259-023-06130-6","article-title":"Noninvasive evaluation of PD-L1 expression in non-small cell lung cancer by immune PET imaging using an acylating agent\u2013modified antibody fragment","volume":"50","author":"Cheng","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2026.115145_bb0090","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00259-020-05025-0","article-title":"PET\/MRI in prostate cancer: a systematic review and meta-analysis","volume":"48","author":"Evangelista","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2026.115145_bb0095","first-page":"255","article-title":"Radiotheranostics in oncology: making precision medicine possible","volume":"73","author":"Aboagye","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jconrel.2026.115145_bb0100","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1148\/radiol.2017170346","article-title":"Radiotheranostics in cancer diagnosis and management","volume":"286","author":"Jadvar","year":"2018","journal-title":"Radiology"},{"key":"10.1016\/j.jconrel.2026.115145_bb0105","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1016\/S1470-2045(19)30821-6","article-title":"Radiotheranostics: a roadmap for future development","volume":"21","author":"Herrmann","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2026.115145_bb0110","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1158\/1078-0432.CCR-22-0159","article-title":"A paradigm of cancer immunotherapy based on 2-[18F]FDG and anti-PD-L1 mAb combination to enhance the antitumor effect","volume":"28","author":"Wen","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115145_bb0115","doi-asserted-by":"crossref","first-page":"7948","DOI":"10.7150\/thno.39203","article-title":"Integrin \u03b1v\u03b23-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy","volume":"9","author":"Chen","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2026.115145_bb0120","doi-asserted-by":"crossref","first-page":"767","DOI":"10.7150\/thno.79806","article-title":"Radiopharmaceuticals heat anti-tumor immunity","volume":"13","author":"Sun","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2026.115145_bb0125","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1021\/acs.bioconjchem.2c00408","article-title":"Synergism of 64Cu-labeled RGD with anti-PD-L1 immunotherapy for the long-acting antitumor effect","volume":"33","author":"Wen","year":"2022","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2026.115145_bb0130","article-title":"FAP-targeted radioligand therapy with 68Ga\/177Lu-DOTA-2P(FAPI)2 enhance immunogenicity and synergize with PD-L1 inhibitors for improved antitumor efficacy","volume":"13","author":"Chen","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2026.115145_bb0135","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2967\/jnumed.119.226712","article-title":"PET imaging of tumor PD-L1 expression with a highly specific nonblocking single-domain antibody","volume":"61","author":"Lv","year":"2020","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2026.115145_bb0140","doi-asserted-by":"crossref","first-page":"9577","DOI":"10.1021\/acs.jmedchem.3c00254","article-title":"Design, synthesis, and biological evaluation of 2-Hydroxy-4-phenylthiophene-3-carbonitrile as PD-L1 antagonist and its comparison to available small molecular PD-L1 inhibitors","volume":"66","author":"Wa\u017cy\u0144ska","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.115145_bb0145","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3390\/ph16020213","article-title":"Design, synthesis, and biological evaluation of a small-molecule PET agent for imaging PD-L1 expression","volume":"16","author":"Xu","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jconrel.2026.115145_bb0150","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00259-023-06480-1","article-title":"Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy","volume":"51","author":"Zhu","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2026.115145_bb0155","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1007\/s00259-024-06610-3","article-title":"Development of small-molecular-based radiotracers for PET imaging of PD-L1 expression and guiding the PD-L1 therapeutics","volume":"51","author":"Yang","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2026.115145_bb0160","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00259-024-06962-w","article-title":"Nuclear imaging of PD-L1 expression promotes the synergistic antitumor efficacy of targeted radionuclide therapy and immune checkpoint blockade","volume":"52","author":"Shi","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2026.115145_bb0165","article-title":"Engineered iron-based metal-organic frameworks nanoplatforms for cancer theranostics: a mini review","volume":"36","author":"Li","year":"2025","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.jconrel.2026.115145_bb0170","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1158\/2326-6066.CIR-22-0953","article-title":"Regulation of PD-L1 trafficking from synthesis to degradation","volume":"11","author":"Lemma","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jconrel.2026.115145_bb0175","doi-asserted-by":"crossref","first-page":"5582","DOI":"10.3390\/ijms26125582","article-title":"Emerging concepts of targeted protein degrader technologies via lysosomal pathways","volume":"26","author":"Alam","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.115145_bb0180","first-page":"4567","article-title":"PD-L1 trafficking and degradation: mechanisms and therapeutic implications","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115145_bb0185","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1007\/s00262-021-02883-x","article-title":"Heterogeneity of PD-L1 expression between invasive and lepidic components of lung adenocarcinomas","volume":"70","author":"Hazim","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2026.115145_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1392546","article-title":"PTMs of PD-1\/PD-L1 and PROTACs application for improving cancer immunotherapy","volume":"15","author":"Ren","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115145_bb0195","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1007\/s00259-023-06229-w","article-title":"Development of [177Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression","volume":"50","author":"Wen","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2026.115145_bb0200","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1038\/s41467-024-48597-3","article-title":"Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation","volume":"15","author":"Xu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115145_bb0205","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41589-018-0161-x","article-title":"HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity","volume":"15","author":"Wang","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.jconrel.2026.115145_bb0210","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.3390\/pharmaceutics15071840","article-title":"Recent developments in PET and SPECT radiotracers as radiopharmaceuticals for hypoxia tumors","volume":"15","author":"Nguyen","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.115145_bb0215","first-page":"1157","article-title":"The radiation-induced proteasome response","volume":"77","author":"Pervan","year":"2001","journal-title":"Int. J. Radiat. Biol."},{"key":"10.1016\/j.jconrel.2026.115145_bb0220","doi-asserted-by":"crossref","first-page":"15111","DOI":"10.1038\/s41467-017-01883-9","article-title":"DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells","volume":"8","author":"Sato","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115145_bb0225","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2026.115145_bb0230","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41392-024-01983-1","article-title":"Sequential responsive nano-PROTACs for precise intracellular delivery and enhanced degradation efficacy in colorectal cancer therapy","volume":"9","author":"Yang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.115145_bb0235","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1039\/D3SC04249A","article-title":"Cooperatively designed aptamer-PROTACs for spatioselective degradation of nucleocytoplasmic shuttling protein for enhanced combinational therapy","volume":"15","author":"Liu","year":"2023","journal-title":"Chem. Sci."},{"key":"10.1016\/j.jconrel.2026.115145_bb0240","first-page":"919","article-title":"Targeting transmembrane proteins with proteolysis-targeting chimeras","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115145_bb0245","article-title":"Ubiquitination of PD-L1 intracellular domain mediates its endocytosis and lysosomal degradation induced by PROTACs","volume":"39","author":"Li","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.jconrel.2026.115145_bb0250","first-page":"45","article-title":"Assays to characterize PROTAC-mediated protein degradation","volume":"2476","author":"Bond","year":"2022","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jconrel.2026.115145_bb0255","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.cell.2017.11.035","article-title":"On the design of combination cancer therapy","volume":"171","author":"Doroshow","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115145_bb0260","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1038\/s41467-018-07131-y","article-title":"Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer","volume":"9","author":"Niemeijer","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115145_bb0265","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2967\/jnumed.121.262045","article-title":"First-in-humans evaluation of a PD-L1-binding peptide PET radiotracer in non-small cell lung Cancer patients","volume":"63","author":"Zhou","year":"2022","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2026.115145_bb0270","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1158\/1078-0432.CCR-25-0160","article-title":"68Ga-NK224 PET\/CT for noninvasive evaluation of PD-L1 expression and Intertumor heterogeneity: a translational exploratory study","volume":"31","author":"Zhao","year":"2025","journal-title":"Clin. Cancer Res."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926005481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926005481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T04:27:49Z","timestamp":1787804869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926005481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":54,"alternative-id":["S0168365926005481"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115145","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrating PD-L1-targeted radioligand with protein degradation for precision tumor theranostics","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115145","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115145"}}